These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27780925)

  • 1. Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.
    Li JP; Huang ZJ; Lu XS; Zhou YC; Shao Y; He XP; Chen SR; Wang DD; Qin LS; Sun WH
    Oncotarget; 2016 Nov; 7(47):77815-77824. PubMed ID: 27780925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms.
    Zhang S; Deng Z; Yao C; Huang P; Zhang Y; Cao S; Li X
    PLoS One; 2017; 12(1):e0169585. PubMed ID: 28081222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
    Zhijun H; Shusheng W; Han M; Jianping L; Li-Sen Q; Dechun L
    Tumour Biol; 2016 Aug; 37(8):10257-67. PubMed ID: 26831668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective β2-AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR-Akt/ERK1/2 Signaling, G1-Phase Arrest, and Apoptosis.
    Chin CC; Li JM; Lee KF; Huang YC; Wang KC; Lai HC; Cheng CC; Kuo YH; Shi CS
    J Cell Physiol; 2016 Feb; 231(2):459-72. PubMed ID: 26189563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C6 ceramide motivates the anticancer sensibility induced by PKC412 in preclinical head and neck squamous cell carcinoma models.
    Zhu Y; Wang C; Zhou Y; Ma N; Zhou J
    J Cell Physiol; 2018 Dec; 233(12):9437-9446. PubMed ID: 29968910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.
    Wu L; Zhang J; Wu H; Han E
    Biochem Biophys Res Commun; 2015 Oct; 466(3):547-53. PubMed ID: 26381179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
    Signore M; Buccarelli M; Pilozzi E; De Luca G; Cappellari M; Fanciulli M; Goeman F; Melucci E; Biffoni M; Ricci-Vitiani L
    Oncotarget; 2016 Jul; 7(28):44113-44128. PubMed ID: 27286453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C.
    Tenzer A; Zingg D; Rocha S; Hemmings B; Fabbro D; Glanzmann C; Schubiger PA; Bodis S; Pruschy M
    Cancer Res; 2001 Nov; 61(22):8203-10. PubMed ID: 11719451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Icaritin activates JNK-dependent mPTP necrosis pathway in colorectal cancer cells.
    Zhou C; Chen Z; Lu X; Wu H; Yang Q; Xu D
    Tumour Biol; 2016 Mar; 37(3):3135-44. PubMed ID: 26427664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
    Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
    Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.
    Shao Z; Bao Q; Jiang F; Qian H; Fang Q; Hu X
    PLoS One; 2015; 10(7):e0132655. PubMed ID: 26204252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts.
    Wiegering A; Korb D; Thalheimer A; Kämmerer U; Allmanritter J; Matthes N; Linnebacher M; Schlegel N; Klein I; Ergün S; Germer CT; Otto C
    Neoplasia; 2014 Nov; 16(11):972-81. PubMed ID: 25425971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
    Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
    Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decyl caffeic acid inhibits the proliferation of colorectal cancer cells in an autophagy-dependent manner in vitro and in vivo.
    Chen C; Kuo YH; Lin CC; Chao CY; Pai MH; Chiang EI; Tang FY
    PLoS One; 2020; 15(5):e0232832. PubMed ID: 32401800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells.
    Yao TJ; Zhu JH; Peng DF; Cui Z; Zhang C; Lu PH
    Tumour Biol; 2015 Jul; 36(7):5641-8. PubMed ID: 25691251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced efficacy of 5-fluorouracil in combination with a dual histone deacetylase and phosphatidylinositide 3-kinase inhibitor (CUDC-907) in colorectal cancer cells.
    Hamam R; Ali D; Vishnubalaji R; Alsaaran ZF; Chalisserry EP; Alfayez M; Aldahmash A; Alajez NM
    Saudi J Gastroenterol; 2017; 23(1):34-38. PubMed ID: 28139498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412.
    Zaugg K; Rocha S; Resch H; Hegyi I; Oehler C; Glanzmann C; Fabbro D; Bodis S; Pruschy M
    Cancer Res; 2001 Jan; 61(2):732-8. PubMed ID: 11212276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical study of cinobufagin as a promising anti-colorectal cancer agent.
    Lu XS; Qiao YB; Li Y; Yang B; Chen MB; Xing CG
    Oncotarget; 2017 Jan; 8(1):988-998. PubMed ID: 27894091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PKC412--a protein kinase inhibitor with a broad therapeutic potential.
    Fabbro D; Ruetz S; Bodis S; Pruschy M; Csermak K; Man A; Campochiaro P; Wood J; O'Reilly T; Meyer T
    Anticancer Drug Des; 2000 Feb; 15(1):17-28. PubMed ID: 10888033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resveratrol elicits anti-colorectal cancer effect by activating miR-34c-KITLG in vitro and in vivo.
    Yang S; Li W; Sun H; Wu B; Ji F; Sun T; Chang H; Shen P; Wang Y; Zhou D
    BMC Cancer; 2015 Dec; 15():969. PubMed ID: 26674205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.